This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068. The trial participants will be randomised to 4 different treatments in trial, receiving trial products in a pre-defined order.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Single, simultaneous dose of NN9068, injected s.c. (under the skin)
Single, simultaneous dose of NN1250, injected s.c. (under the skin)
Single, simultaneous dose of NN2211, injected s.c. (under the skin)
Novo Nordisk Investigational Site
Neuss, Germany
Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes
Time frame: assessed 0-96 hours after trial product administration
The area under the NN2211 concentration-time curve after single-dose
Time frame: assessed 0-72 hours after trial product administration
The area under the NN1250 concentration-time curve after single-dose
Time frame: assessed 0-96 hours after trial product administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single, simultaneous dose of placebo, injected s.c. (under the skin)